

John K Hsiao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8842817/publications.pdf>

Version: 2024-02-01

58
papers

14,517
citations

87888

38
h-index

138484

58
g-index

59
all docs

59
docs citations

59
times ranked

9076
citing authors

#	ARTICLE	IF	CITATIONS
1	A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensemble and on multivariate algorithms, to characterize late onset Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 12063.	3.3	11
2	Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 797-808.	2.4	12
3	Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 449-459.	4.3	65
4	Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. <i>American Journal of Psychiatry</i> , 2011, 168, 831-839.	7.2	232
5	Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study. <i>American Journal of Psychiatry</i> , 2009, 166, 583-590.	7.2	76
6	Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. <i>Biological Psychiatry</i> , 2009, 66, 1013-1022.	1.3	91
7	Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009, 107, 1-12.	2.0	129
8	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. <i>Schizophrenia Research</i> , 2008, 100, 39-52.	2.0	53
9	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. <i>Schizophrenia Research</i> , 2008, 101, 273-286.	2.0	258
10	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008, 103, 104-109.	2.0	64
11	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008, 105, 175-187.	2.0	195
12	Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial. <i>American Journal of Psychiatry</i> , 2008, 165, 844-854.	7.2	274
13	Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial. <i>Psychiatric Services</i> , 2008, 59, 500-506.	2.0	110
14	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 103-111.	1.4	24
15	Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2007, 64, 1259.	12.3	57
16	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633.	12.3	928
17	Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 428-436.	7.2	246
18	Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 415-427.	7.2	138

#	ARTICLE	IF	CITATIONS
19	Dr. Rosenheck and Colleagues Reply. American Journal of Psychiatry, 2007, 164, 678-680.	7.2	7
20	Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. New England Journal of Medicine, 2006, 355, 1525-1538.	27.0	1,067
21	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. American Journal of Psychiatry, 2006, 163, 611-622.	7.2	312
22	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal of Psychiatry, 2006, 163, 2080-2089.	7.2	247
23	Interpreting the Results of the CATIE Study. Psychiatric Services, 2006, 57, 139-139.	2.0	18
24	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. Focus (American J Psychiatry), 2006, 13, 10-10.	7.2	10
25	Barriers to Employment for People With Schizophrenia. American Journal of Psychiatry, 2006, 163, 411-417.	7.2	390
26	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. American Journal of Psychiatry, 2006, 163, 600-610.	7.2	760
27	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. American Journal of Psychiatry, 2006, 163, 600.	7.2	513
28	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. American Journal of Psychiatry, 2006, 163, 611.	7.2	221
29	Measuring outcome priorities and preferences in people with schizophrenia. British Journal of Psychiatry, 2005, 187, 529-536.	2.8	74
30	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine, 2005, 353, 1209-1223.	27.0	5,335
31	Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 2005, 80, 19-32.	2.0	1,016
32	National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. American Journal of Geriatric Psychiatry, 2001, 9, 346-360.	1.2	156
33	Medication-free Intervals and Schizophrenia Research—Editors' Introduction. Schizophrenia Bulletin, 1997, 23, 1-1.	4.3	3
34	Dose-dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans. Psychopharmacology, 1993, 111, 295-300.	3.1	9
35	Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology, 1993, 112, S76-S84.	3.1	27
36	The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. I. Regional Changes in Cerebral Glucose Metabolism Differentiating Patients and Controls. Neuropsychopharmacology, 1993, 9, 277-291.	5.4	166

#	ARTICLE	IF	CITATIONS
37	ECT treatment does not enhance neuroendocrine responses to serotonergic challenge. <i>Journal of Psychopharmacology</i> , 1992, 6, 501-508.	4.0	2
38	REGIONAL BRAIN METABOLISM AS PREDICTORS OF CLOZAPINE RESPONSE. <i>Clinical Neuropharmacology</i> , 1992, 15, 399A-400A.	0.7	3
39	Lithium administration modulates platelet Gi in humans. <i>Life Sciences</i> , 1992, 50, 227-233.	4.3	39
40	In Vivo Evidence that Lithium Inactivates GiModulation of Adenylate Cyclase in Brain. <i>Journal of Neurochemistry</i> , 1992, 59, 200-205.	3.9	73
41	Quantitative Examination of Tissue Concentration Profiles Associated with Microdialysis. <i>Journal of Neurochemistry</i> , 1992, 58, 931-940.	3.9	141
42	Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. <i>Brain Research</i> , 1991, 538, 333-336.	2.2	42
43	Quantitative microdialysis. <i>Handbook of Behavioral Neuroscience</i> , 1991, 7, 47-80.	0.0	35
44	Quantitative Microdialysis: Analysis of Transients and Application to Pharmacokinetics in Brain. <i>Journal of Neurochemistry</i> , 1991, 57, 103-119.	3.9	135
45	Effects of Different Semipermeable Membranes on In Vitro and In Vivo Performance of Microdialysis Probes. <i>Journal of Neurochemistry</i> , 1990, 54, 1449-1452.	3.9	133
46	Abnormal neuroendocrine responsivity to acute I.V. clomipramine challenge in depressed patients. <i>Psychiatry Research</i> , 1990, 31, 39-47.	3.3	48
47	Methodology of microdialysis of neostriatum in hemiparkinsonian nonhuman primates. <i>Experimental Neurology</i> , 1990, 110, 181-186.	4.1	23
48	In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. <i>Experimental Neurology</i> , 1990, 110, 187-193.	4.1	27
49	Diagnosing Diagnoses. <i>Archives of General Psychiatry</i> , 1989, 46, 664.	12.3	263
50	The Effects of Intravenous Clomipramine on Neurohormones in Normal Subjects*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 68, 632-637.	3.6	62
51	Intravenous alprazolam challenge in normal subjects. <i>Psychopharmacology</i> , 1989, 99, 508-514.	3.1	32
52	Activation in young rats induced by LY134046, an inhibitor of phenylethanolamine N-methyltransferase. <i>Psychopharmacology</i> , 1989, 98, 240-244.	3.1	2
53	Monoamine Neurotransmitter Interactions and the Prediction of Antidepressant Response. <i>Archives of General Psychiatry</i> , 1987, 44, 1078.	12.3	54
54	Cardiovascular response to speaking in schizophrenics. <i>Psychiatry Research</i> , 1987, 22, 69-79.	3.3	2

#	ARTICLE	IF	CITATIONS
55	The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 547-554.	4.7	40
56	ECT and Neurological Disorders. <i>Convulsive Therapy</i> , 1987, 3, 121-136.	0.1	15
57	Is there paradoxical growth hormone response to thyrotropin-releasing hormone in depression?. <i>Biological Psychiatry</i> , 1986, 21, 595-600.	1.3	16
58	A study of the TRH test in a family with psychiatric illness: A reflection on the TRH test as a state-trait marker. <i>Biological Psychiatry</i> , 1985, 20, 570-572.	1.3	29